The clinical trial, sponsored by The First Affiliated Hospital of Soochow University, is investigating the efficacy of HMA maintenance therapy in patients with favorable-risk Acute Myeloid Leukemia (AML). Given the increasing incidence of AML and the limited treatment options for this patient population, successful outcomes could position the sponsor as a leader in the HMA market. The trial's focus on overall survival (OS) and relapse-free survival (RFS) could enhance the commercial viability of Azacitidine and Decitabine, particularly in the context of personalized medicine. The competitive landscape includes other emerging therapies targeting AML, necessitating robust data to demonstrate superiority or added benefit. Diligence should focus on regulatory pathways and potential market access challenges in various jurisdictions.